Lessons learned from the SARS-CoV-2 pandemic; from nucleic acid nanomedicines, to clinical trials, herd immunity, and the vaccination divide.

Abstract

INTRODUCTION:

In November 2019, the idea of a zoonotic virus crossing over to human transmission in a seafood market in Wuhan, China, and then soaring across the globe to claim over 6.3 million lives and persisting to date, seemed more like wild science fiction than a future reality. As the SARS-CoV-2 pandemic continues, it is important to hallmark the imprints the pandemic has made on science.

AREAS COVERED:

This review covers the biology of SARS-CoV-2, vaccine formulations and trials, the concept of 'herd resistance,' and the vaccination divide.

EXPERT OPINION:

The SARS-CoV-2 pandemic has changed the landscape of medicine. The rapid approval of SARS-CoV-2 vaccines has changed the culture of drug development and clinical approvals. This change is already leading to more accelerated trials. The RNA vaccines have opened the market for nucleic acid therapies and the applications are limitless - from cancer to influenza. A phenomenon that has occurred is that the low efficacy of current vaccines and the rapid mutation rate of the virus is preventing herd immunity from being attained. Instead, herd resistance is being acquired. Even with future, more effective vaccines, anti-vaccination attitudes will continue to challenge the quest for SARS-CoV-2 herd immunity.

• Authors: Hiba Hussain, Aishwarya Ganesh, Lara Milane, Mansoor Amiji
• Journal: Expert opinion on drug delivery (Expert Opin Drug Deliv) Vol. 20 Issue 4 Pg. 489-506 (04 2023) ISSN: 1744-7593 [Electronic] England
• PMID: 36890642 (Publication Type: Review, Journal Article)

Chemical References

• COVID-19 Vaccines
• Nucleic Acids

Topics

• Humans
• Pandemics (prevention & control)
• SARS-CoV-2
• COVID-19 Vaccines
• Immunity, Herd
• Nanomedicine
• COVID-19 (prevention & control)
• Nucleic Acids